{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:35:14Z","timestamp":1792798514060,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00467-025-06789-z","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T22:25:23Z","timestamp":1746051923000},"page":"33-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gut microbiota-targeted therapies in pediatric chronic kidney disease: gaps and opportunities"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-0788","authenticated-orcid":false,"given":"Arpana","family":"Iyengar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balamurugan","family":"Ramadass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"6789_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","volume":"113","author":"EZ Gomaa","year":"2020","unstructured":"Gomaa EZ (2020) Human gut microbiota\/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek 113:2019\u20132040. https:\/\/doi.org\/10.1007\/s10482-020-01474-7","journal-title":"Antonie Van Leeuwenhoek"},{"key":"6789_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2020.08.065","volume":"160","author":"V Ronan","year":"2021","unstructured":"Ronan V, Yeasin R, Claud EC (2021) Childhood development and the microbiome\u2014the intestinal microbiota in maintenance of health and development of disease during childhood development. Gastroenterology 160:495\u2013506. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.065","journal-title":"Gastroenterology"},{"key":"6789_CR3","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3390\/app13053212","volume":"13","author":"A Zupcic","year":"2023","unstructured":"Zupcic A, Slezak P, Radloff J (2023) The gastrointestinal microbiota as a potential cause and target in chronic kidney disease accentuating treatment and intervention strategies. Applied Sci 13:3212. https:\/\/doi.org\/10.3390\/app13053212","journal-title":"Applied Sci"},{"key":"6789_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00467-024-06357-x","volume":"40","author":"K Kusumi","year":"2024","unstructured":"Kusumi K, Islam MS, Banker H et al (2024) Navigating the microbial maze: unraveling the connection between gut microbiome and pediatric kidney and urinary tract disease. Pediatr Nephrol 40:339\u2013353. https:\/\/doi.org\/10.1007\/s00467-024-06357-x","journal-title":"Pediatr Nephrol"},{"key":"6789_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40348-021-00126-8","volume":"8","author":"J Schlender","year":"2021","unstructured":"Schlender J, Behrens F, McParland V et al (2021) Bacterial metabolites and cardiovascular risk in children with chronic kidney disease. Mol Cell Pediatr 8:17. https:\/\/doi.org\/10.1186\/s40348-021-00126-8","journal-title":"Mol Cell Pediatr"},{"key":"6789_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/asn.2022030378","volume":"33","author":"J Holle","year":"2022","unstructured":"Holle J, Bartolomaeus H, Lober U et al (2022) Inflammation in children with CKD linked to gut dysbiosis and metabolite imbalance. J Am Soc Nephrol 33:2259\u20132275. https:\/\/doi.org\/10.1681\/asn.2022030378","journal-title":"J Am Soc Nephrol"},{"key":"6789_CR7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3390\/ijms21061986","volume":"21","author":"T Gryp","year":"2020","unstructured":"Gryp T, Huys GRB, Joossens M et al (2020) Isolation and quantification of uremic toxin precursor-generating gut bacteria in chronic kidney disease patients. International J Mol Sci 21:1986. https:\/\/doi.org\/10.3390\/ijms21061986","journal-title":"International J Mol Sci"},{"key":"6789_CR8","doi-asserted-by":"publisher","first-page":"e0240446","DOI":"10.1371\/journal.pone.0240446","volume":"15","author":"J Holle","year":"2020","unstructured":"Holle J, Kirchner M, Okun J et al (2020) Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children. PLoS ONE 15:e0240446. https:\/\/doi.org\/10.1371\/journal.pone.0240446","journal-title":"PLoS ONE"},{"key":"6789_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/circresaha.116.305360","volume":"116","author":"WHW Tang","year":"2015","unstructured":"Tang WHW, Wang Z, Kennedy DJ et al (2015) Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116:448\u2013455. https:\/\/doi.org\/10.1161\/circresaha.116.305360","journal-title":"Circ Res"},{"key":"6789_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000381990","volume":"130","author":"WL Lau","year":"2015","unstructured":"Lau WL, Kalantar-Zadeh K, Vaziri ND (2015) The gut as a source of inflammation in chronic kidney disease. Nephron 130:92\u201398. https:\/\/doi.org\/10.1159\/000381990","journal-title":"Nephron"},{"key":"6789_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40168-016-0195-9","volume":"4","author":"J Crespo-Salgado","year":"2016","unstructured":"Crespo-Salgado J, Vehaskari VM, Stewart T et al (2016) Intestinal microbiota in pediatric patients with end stage renal disease: A Midwest Pediatric Nephrology Consortium Study. Microbiome 4:50. https:\/\/doi.org\/10.1186\/s40168-016-0195-9","journal-title":"Microbiome"},{"key":"6789_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1186\/s12967-024-05578-w","volume":"22","author":"J Li","year":"2024","unstructured":"Li J, Shen Y, Yan K et al (2024) The compositional and functional imbalance of the gut microbiota in CKD linked to disease patterns. J Transl Med 22:773. https:\/\/doi.org\/10.1186\/s12967-024-05578-w","journal-title":"J Transl Med"},{"key":"6789_CR13","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s00467-019-04331-6","volume":"34","author":"J Holle","year":"2019","unstructured":"Holle J, Querfeld U, Kirchner M et al (2019) Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. Pediatr Nephrol 34:2571\u20132582. https:\/\/doi.org\/10.1007\/s00467-019-04331-6","journal-title":"Pediatr Nephrol"},{"key":"6789_CR14","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.ekir.2024.03.021","volume":"9","author":"E Snauwaert","year":"2024","unstructured":"Snauwaert E, De Buyser S, Van Biesen W et al (2024) Indoxyl sulfate contributes to impaired height velocity in (pre)school children. Kidney Int Rep 9:1674\u20131683. https:\/\/doi.org\/10.1016\/j.ekir.2024.03.021","journal-title":"Kidney Int Rep"},{"key":"6789_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/mnh.0000000000000565","volume":"29","author":"G Caggiano","year":"2020","unstructured":"Caggiano G, Cosola C, Di Leo V et al (2020) Microbiome modulation to correct uremic toxins and to preserve kidney functions. Curr Opin Nephrol Hypertens 29:49\u201356. https:\/\/doi.org\/10.1097\/mnh.0000000000000565","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6789_CR16","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/s41467-018-05184-7","volume":"9","author":"MA Jackson","year":"2018","unstructured":"Jackson MA, Verdi S, Maxan M-E et al (2018) Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Comm 9:2655. https:\/\/doi.org\/10.1038\/s41467-018-05184-7","journal-title":"Nat Comm"},{"key":"6789_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ncp.10662","volume":"37","author":"M Ribeiro","year":"2021","unstructured":"Ribeiro M, Fonseca L, Anjos JS et al (2021) Oral iron supplementation in patients with chronic kidney disease: can it be harmful to the gut microbiota? Nutr Clin Pract 37:81\u201393. https:\/\/doi.org\/10.1002\/ncp.10662","journal-title":"Nutr Clin Pract"},{"key":"6789_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10157-020-01892-x","volume":"24","author":"A Iguchi","year":"2020","unstructured":"Iguchi A, Yamamoto S, Oda A et al (2020) Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis. Clin Exp Nephrol 24:725\u2013733. https:\/\/doi.org\/10.1007\/s10157-020-01892-x","journal-title":"Clin Exp Nephrol"},{"key":"6789_CR19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3390\/microorganisms8122040","volume":"8","author":"P-H Wu","year":"2020","unstructured":"Wu P-H, Liu P-Y, Chiu Y-W et al (2020) Comparative gut microbiome differences between ferric citrate and calcium carbonate phosphate binders in patients with end-stage kidney disease. Microorganisms 8:2040. https:\/\/doi.org\/10.3390\/microorganisms8122040","journal-title":"Microorganisms"},{"key":"6789_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1124\/jpet.118.251389","volume":"367","author":"WL Lau","year":"2018","unstructured":"Lau WL, Vaziri ND, Nunes ACF et al (2018) The phosphate binder ferric citrate alters the gut microbiome in rats with chronic kidney disease. J Pharmacol Exp Ther 367:452\u2013460. https:\/\/doi.org\/10.1124\/jpet.118.251389","journal-title":"J Pharmacol Exp Ther"},{"key":"6789_CR21","doi-asserted-by":"publisher","first-page":"172892","DOI":"10.1016\/j.ejphar.2019.172892","volume":"868","author":"Y Rahbar Saadat","year":"2020","unstructured":"Rahbar Saadat Y, Niknafs B, Hosseiniyan Khatibi SM et al (2020) Gut microbiota; an overlooked effect of phosphate binders. Eur J Pharmacol 868:172892. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172892","journal-title":"Eur J Pharmacol"},{"key":"6789_CR22","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.4103\/0366-6999.246059","volume":"131","author":"YY Miao","year":"2018","unstructured":"Miao YY, Xu CM, Xia M et al (2018) Relationship between gut microbiota and phosphorus metabolism in hemodialysis patients: a preliminary exploration. Chin Med J 131:2792\u20132799. https:\/\/doi.org\/10.4103\/0366-6999.246059","journal-title":"Chin Med J"},{"key":"6789_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41581-022-00647-z","volume":"19","author":"H Krukowski","year":"2022","unstructured":"Krukowski H, Valkenburg S, Madella A-M et al (2022) Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential. Nat Rev Nephrol 19:87\u2013101. https:\/\/doi.org\/10.1038\/s41581-022-00647-z","journal-title":"Nat Rev Nephrol"},{"key":"6789_CR24","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1053\/j.jrn.2022.12.004","volume":"33","author":"K Lambert","year":"2023","unstructured":"Lambert K, Rinninella E, Biruete A et al (2023) Targeting the gut microbiota in kidney disease: the future in renal nutrition and metabolism. J Ren Nutr 33:S30\u2013S39. https:\/\/doi.org\/10.1053\/j.jrn.2022.12.004","journal-title":"J Ren Nutr"},{"key":"6789_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/mnh.0000000000000661","volume":"30","author":"K Sumida","year":"2021","unstructured":"Sumida K, Lau WL, Kovesdy CP et al (2021) Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens 30:75\u201384. https:\/\/doi.org\/10.1097\/mnh.0000000000000661","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6789_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1080\/10408398.2020.1761771","volume":"61","author":"M Ondrussek-Sekac","year":"2020","unstructured":"Ondrussek-Sekac M, Navas-Carrillo D, Orenes-Pi\u00f1ero E (2020) Intestinal microbiota alterations in chronic kidney disease and the influence of dietary components. Crit Rev Food Sci Nutr 61:1490\u20131502. https:\/\/doi.org\/10.1080\/10408398.2020.1761771","journal-title":"Crit Rev Food Sci Nutr"},{"key":"6789_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/mnh.0000000000000753","volume":"31","author":"K Sumida","year":"2021","unstructured":"Sumida K, Lau WL, Kalantar-Zadeh K, Kovesdy CP (2021) Novel intestinal dialysis interventions and microbiome modulation to control uremia. Curr Opin Nephrol Hypertens 31:82\u201391. https:\/\/doi.org\/10.1097\/mnh.0000000000000753","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"6789_CR28","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.7150\/ijms.66451","volume":"18","author":"C-K Hsu","year":"2021","unstructured":"Hsu C-K, Su S-C, Chang L-C et al (2021) Effects of low protein diet on modulating gut microbiota in patients with chronic kidney disease: a systematic review and meta-analysis of International Studies. Int J Med Sci 18:3839\u20133850. https:\/\/doi.org\/10.7150\/ijms.66451","journal-title":"Int J Med Sci"},{"key":"6789_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41581-020-0297-2","volume":"16","author":"JJ Carrero","year":"2020","unstructured":"Carrero JJ, Gonz\u00e1lez-Ortiz A, Avesani CM et al (2020) Plant-based diets to manage the risks and complications of chronic kidney disease. Nat Rev Nephrol 16:525\u2013542. https:\/\/doi.org\/10.1038\/s41581-020-0297-2","journal-title":"Nat Rev Nephrol"},{"key":"6789_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1590\/2175-8239-JBN-2022-0021pt","volume":"45","author":"\u00c9MR de Ara\u00fajo","year":"2022","unstructured":"de Ara\u00fajo \u00c9MR, Meneses GC, Carioca AAF et al (2022) Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. Braz J Nephrol 45:152\u2013161. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2022-0021pt","journal-title":"Braz J Nephrol"},{"key":"6789_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1053\/j.jrn.2018.01.018","volume":"28","author":"M Rossi","year":"2018","unstructured":"Rossi M, Klein K, Johnson DW et al (2018) Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. J Ren Nutr 28:403\u2013412. https:\/\/doi.org\/10.1053\/j.jrn.2018.01.018","journal-title":"J Ren Nutr"},{"key":"6789_CR32","doi-asserted-by":"publisher","first-page":"105419","DOI":"10.1016\/j.jff.2024.105419","volume":"112","author":"S Jiang","year":"2024","unstructured":"Jiang S, Xie S, Lv D et al (2024) Effect of soluble dietary fiber on gut microbiota and derived metabolites in stage 3 to 5 chronic kidney disease patients: a randomized controlled trial. J Func Foods 112:105419. https:\/\/doi.org\/10.1016\/j.jff.2024.105419","journal-title":"J Func Foods"},{"key":"6789_CR33","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1186\/s12986-019-0343-x","volume":"8","author":"VM Krishnamurthy","year":"2019","unstructured":"Krishnamurthy VM, Wei G, Baird BC et al (2019) Effects of fermentable high fiber diet supplementation on gut-derived and conventional nitrogenous products in patients on maintenance hemodialysis: a randomized controlled trial. J Nutr Sci 8:e18. https:\/\/doi.org\/10.1186\/s12986-019-0343-x","journal-title":"J Nutr Sci"},{"key":"6789_CR34","doi-asserted-by":"publisher","unstructured":"Srivastava A, Raj DS (2024) Effects of prebiotic on metagenome and lipid metabolism in CKD patients. J Am Soc Nephrol 35:https:\/\/doi.org\/10.1681\/ASN.20244092w89q. https:\/\/doi.org\/10.1681\/ASN.20244092w89q","DOI":"10.1681\/ASN.20244092w89q"},{"key":"6789_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/10408398.2020.1733480","volume":"61","author":"HJ Zheng","year":"2021","unstructured":"Zheng HJ, Guo J, Wang Q et al (2021) Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 61:577\u2013598. https:\/\/doi.org\/10.1080\/10408398.2020.1733480","journal-title":"Crit Rev Food Sci Nutr"},{"key":"6789_CR36","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.3390\/molecules26196076","volume":"26","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang P, Zhang X (2021) Probiotics regulate gut microbiota: an effective method to improve immunity. Molecules 26:6076. https:\/\/doi.org\/10.3390\/molecules26196076","journal-title":"Molecules"},{"key":"6789_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12602-018-9411-1","volume":"28","author":"NA Borges","year":"2018","unstructured":"Borges NA, Stenvinkel P, Bergman P et al (2018) Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. J Ren Nutr 28:403\u2013412. https:\/\/doi.org\/10.1007\/s12602-018-9411-1","journal-title":"J Ren Nutr"},{"key":"6789_CR38","doi-asserted-by":"publisher","first-page":"111217","DOI":"10.1016\/j.nut.2021.111217","volume":"89","author":"ESV Rezende","year":"2021","unstructured":"Rezende ESV, Lima GC, Naves MMV (2021) Dietary fibers as beneficial microbiota modulators: a proposed classification by prebiotic categories. Nutrition 89:111217. https:\/\/doi.org\/10.1016\/j.nut.2021.111217","journal-title":"Nutrition"},{"key":"6789_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","volume":"14","author":"GR Gibson","year":"2017","unstructured":"Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ et al (2017) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14:491\u2013502. https:\/\/doi.org\/10.1038\/nrgastro.2017.75","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6789_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/toxins13030225","volume":"13","author":"A El Amouri","year":"2021","unstructured":"El Amouri A, Snauwaert E, Foulon A et al (2021) Dietary fibre intake is associated with serum levels of uremic toxins in children with chronic kidney disease. Toxins 13:225. https:\/\/doi.org\/10.3390\/toxins13030225","journal-title":"Toxins"},{"key":"6789_CR41","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00467-020-04840-9","volume":"36","author":"A El Amouri","year":"2021","unstructured":"El Amouri A, Snauwaert E, Foulon A et al (2021) Dietary fibre intake is low in paediatric chronic kidney disease patients but its impact on levels of gut-derived uremic toxins remains uncertain. Pediatr Nephrol 36:1589\u20131595. https:\/\/doi.org\/10.1007\/s00467-020-04840-9","journal-title":"Pediatr Nephrol"},{"key":"6789_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1053\/j.jrn.2024.05.008","volume":"35","author":"A Desloovere","year":"2025","unstructured":"Desloovere A, Polderman N, Renken-Terhaerdt J et al (2025) The management of dietary fiber intake in children with chronic kidney disease \u2013 clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. J Ren Nutr 35:207\u2013220. https:\/\/doi.org\/10.1053\/j.jrn.2024.05.008","journal-title":"J Ren Nutr"},{"key":"6789_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/hdi.12753","volume":"23","author":"MR Laffin","year":"2019","unstructured":"Laffin MR, Tayebi Khosroshahi H, Park H et al (2019) Amylose Resistant Starch (ham-rs2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial. Hemodial Int 23:343\u2013347. https:\/\/doi.org\/10.1111\/hdi.12753","journal-title":"Hemodial Int"},{"key":"6789_CR44","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ndt\/gfy171","volume":"34","author":"CI Ramos","year":"2018","unstructured":"Ramos CI, Armani RG, Canziani ME et al (2018) Effect of prebiotic (fructooligosaccharides) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant 34:1876\u20131884. https:\/\/doi.org\/10.1093\/ndt\/gfy171","journal-title":"Nephrol Dial Transplant"},{"key":"6789_CR45","doi-asserted-by":"publisher","first-page":"e0153893","DOI":"10.1371\/journal.pone.0153893","volume":"11","author":"R Poesen","year":"2016","unstructured":"Poesen R, Evenepoel P, de Loor H et al (2016) The influence of Prebiotic Arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS ONE 11:e0153893. https:\/\/doi.org\/10.1371\/journal.pone.0153893","journal-title":"PLoS ONE"},{"key":"6789_CR46","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00467-021-05365-5","volume":"37","author":"A El Amouri","year":"2022","unstructured":"El Amouri A, Delva K, Foulon A et al (2022) Potassium and fiber: a controversial couple in the nutritional management of children with chronic kidney disease. Pediatr Nephrol 37:1657\u20131665. https:\/\/doi.org\/10.1007\/s00467-021-05365-5","journal-title":"Pediatr Nephrol"},{"key":"6789_CR47","doi-asserted-by":"publisher","first-page":"1068613","DOI":"10.3389\/fphar.2022.1068613","volume":"13","author":"L Zheng","year":"2023","unstructured":"Zheng L, Luo M, Zhou H, Chen J (2023) Natural products from plants and microorganisms: novel therapeutics for chronic kidney disease via gut microbiota regulation. Front Pharmacol 13:1068613. https:\/\/doi.org\/10.3389\/fphar.2022.1068613","journal-title":"Front Pharmacol"},{"key":"6789_CR48","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3389\/fphar.2020.01092","volume":"11","author":"C Ji","year":"2020","unstructured":"Ji C, Deng Y, Yang A et al (2020) Rhubarb enema improved colon mucosal barrier injury in 5\/6 nephrectomy rats may associate with gut microbiota modification. Front Pharmacol 11:1092. https:\/\/doi.org\/10.3389\/fphar.2020.01092","journal-title":"Front Pharmacol"},{"key":"6789_CR49","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s11255-022-03182-9","volume":"54","author":"L Alvarenga","year":"2022","unstructured":"Alvarenga L, Cardozo LF, Da Cruz BO et al (2022) Curcumin supplementation improves oxidative stress and inflammation biomarkers in patients undergoing hemodialysis: a secondary analysis of a randomized controlled trial. Int Urol Nephrol 54:2645\u20132652. https:\/\/doi.org\/10.1007\/s11255-022-03182-9","journal-title":"Int Urol Nephrol"},{"key":"6789_CR50","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3390\/nu15102239","volume":"15","author":"J D\u2019andurain","year":"2023","unstructured":"D\u2019andurain J, L\u00f3pez V, Arazo-Rusindo M et al (2023) Effect of curcumin consumption on inflammation and oxidative stress in patients on hemodialysis: a literature review. Nutrients 15:2239. https:\/\/doi.org\/10.3390\/nu15102239","journal-title":"Nutrients"},{"key":"6789_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/nu14010231","volume":"14","author":"F Pivari","year":"2022","unstructured":"Pivari F, Mingione A, Piazzini G et al (2022) Curcumin supplementation (Meriva\u00ae) modulates inflammation, lipid peroxidation and gut microbiota composition in chronic kidney disease. Nutrients 14:231. https:\/\/doi.org\/10.3390\/nu14010231","journal-title":"Nutrients"},{"key":"6789_CR52","doi-asserted-by":"publisher","first-page":"101732","DOI":"10.1016\/j.ctcp.2023.101732","volume":"51","author":"TR Chermut","year":"2023","unstructured":"Chermut TR, Fonseca L, Figueiredo N et al (2023) Effects of propolis on inflammation markers in patients undergoing hemodialysis: a randomized, double-blind controlled clinical trial. Compl Ther Clin Prac 51:101732. https:\/\/doi.org\/10.1016\/j.ctcp.2023.101732","journal-title":"Compl Ther Clin Prac"},{"key":"6789_CR53","doi-asserted-by":"publisher","first-page":"154731","DOI":"10.1016\/j.phymed.2023.154731","volume":"114","author":"BG Baptista","year":"2023","unstructured":"Baptista BG, Fanton S, Ribeiro M et al (2023) The effect of Brazilian green propolis extract on inflammation in patients with chronic kidney disease on peritoneal dialysis: a randomised double-blind controlled clinical trial. Phytomedicine 114:154731. https:\/\/doi.org\/10.1016\/j.phymed.2023.154731","journal-title":"Phytomedicine"},{"key":"6789_CR54","doi-asserted-by":"publisher","first-page":"153561","DOI":"10.1016\/j.phymed.2021.153561","volume":"86","author":"W Lin","year":"2021","unstructured":"Lin W, Li Y, Zhang H et al (2021) The effects of Fushen Granule on the composition and function of the gut microbiota during peritoneal dialysis-related peritonitis. Phytomedicine 86:153561. https:\/\/doi.org\/10.1016\/j.phymed.2021.153561","journal-title":"Phytomedicine"},{"key":"6789_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/nutrit\/nuad048","volume":"82","author":"KS Coutinho-Wolino","year":"2023","unstructured":"Coutinho-Wolino KS, Melo MF, Mota JC et al (2023) Blueberry, cranberry, raspberry, and Strawberry as modulators of the gut microbiota: target for treatment of gut dysbiosis in chronic kidney disease? from current evidence to future possibilities. Nutr Rev 82:248\u2013261. https:\/\/doi.org\/10.1093\/nutrit\/nuad048","journal-title":"Nutr Rev"},{"key":"6789_CR56","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/nu14071527","volume":"14","author":"NK Leeuwendaal","year":"2022","unstructured":"Leeuwendaal NK, Stanton C, O\u2019Toole PW, Beresford TP (2022) Fermented foods, health and the gut microbiome. Nutrients 14:1527. https:\/\/doi.org\/10.3390\/nu14071527","journal-title":"Nutrients"},{"key":"6789_CR57","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/foods12040687","volume":"12","author":"P Patel","year":"2023","unstructured":"Patel P, Butani K, Kumar A et al (2023) Effects of fermented food consumption on non-communicable diseases. Foods 12:687. https:\/\/doi.org\/10.3390\/foods12040687","journal-title":"Foods"},{"key":"6789_CR58","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.3390\/nu12082376","volume":"12","author":"L-X He","year":"2020","unstructured":"He L-X, Abdolmaleky HM, Yin S et al (2020) Dietary fermented soy extract and oligo-lactic acid alleviate chronic kidney disease in 37 via inhibition of inflammation and modulation of gut microbiota. Nutrients 12:2376. https:\/\/doi.org\/10.3390\/nu12082376","journal-title":"Nutrients"},{"key":"6789_CR59","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/ndt\/gfv353","volume":"31","author":"A Yoshifuji","year":"2015","unstructured":"Yoshifuji A, Wakino S, Irie J et al (2015) Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol Dial Transplant 31:401\u2013412. https:\/\/doi.org\/10.1093\/ndt\/gfv353","journal-title":"Nephrol Dial Transplant"},{"key":"6789_CR60","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/fermentation9040391","volume":"9","author":"GA Stuivenberg","year":"2023","unstructured":"Stuivenberg GA, Chmiel JA, Akouris PP et al (2023) Supplementing yogurt with probiotic bifidobacteria to counter chronic kidney disease. Fermentation 9:391. https:\/\/doi.org\/10.3390\/fermentation9040391","journal-title":"Fermentation"},{"key":"6789_CR61","doi-asserted-by":"publisher","first-page":"863779","DOI":"10.3389\/fcimb.2022.863779","volume":"12","author":"Q Che","year":"2022","unstructured":"Che Q, Luo T, Shi J et al (2022) Mechanisms by which traditional Chinese medicines influence the intestinal flora and intestinal barrier. Front Cell Infect Microbiol 12:863779. https:\/\/doi.org\/10.3389\/fcimb.2022.863779","journal-title":"Front Cell Infect Microbiol"},{"key":"6789_CR62","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fphar.2020.00604","volume":"11","author":"L Zheng","year":"2020","unstructured":"Zheng L, Chen S, Wang F et al (2020) Distinct responses of gut microbiota to Jian-pi-yi-shen decoction are associated with improved clinical outcomes in 5\/6 nephrectomised rats. Front Pharmacol 11:604. https:\/\/doi.org\/10.3389\/fphar.2020.00604","journal-title":"Front Pharmacol"},{"key":"6789_CR63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11418-020-01452-3","volume":"75","author":"Q Chen","year":"2020","unstructured":"Chen Q, Ren D, Wu J et al (2020) Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota. J Nat Med 75:84\u201398. https:\/\/doi.org\/10.1007\/s11418-020-01452-3","journal-title":"J Nat Med"},{"key":"6789_CR64","doi-asserted-by":"publisher","first-page":"4602612","DOI":"10.1155\/2021\/4602612","volume":"2021","author":"Y Ming","year":"2021","unstructured":"Ming Y, Cheng S, Long W et al (2021) The herbal formula granule prescription Mahuang decoction ameliorated chronic kidney disease which was associated with restoration of dysbiosis of intestinal microbiota in rats. Evid Based Complement Alternat Med 2021:4602612. https:\/\/doi.org\/10.1155\/2021\/4602612","journal-title":"Evid Based Complement Alternat Med"},{"key":"6789_CR65","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.3390\/nu14194044","volume":"14","author":"N Tian","year":"2022","unstructured":"Tian N, Li L, Ng JK-C, Li PK-T (2022) The potential benefits and controversies of probiotics use in patients at different stages of chronic kidney disease. Nutrients 14:4044. https:\/\/doi.org\/10.3390\/nu14194044","journal-title":"Nutrients"},{"key":"6789_CR66","doi-asserted-by":"publisher","first-page":"765","DOI":"10.18203\/2319-2003.ijbcp20171028","volume":"6","author":"S Srinivasa","year":"2017","unstructured":"Srinivasa S, Madhusudhan SK (2017) A prospective study to evaluate the safety and efficacy of symbiotic supplementation (probiotic and prebiotic combination) in stage 5D chronic kidney disease patients. Int J Basic Clin Pharmacol 6:765\u2013773. https:\/\/doi.org\/10.18203\/2319-2003.ijbcp20171028","journal-title":"Int J Basic Clin Pharmacol"},{"key":"6789_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2215\/cjn.05240515","volume":"11","author":"M Rossi","year":"2016","unstructured":"Rossi M, Johnson DW, Morrison M et al (2016) Synbiotics easing renal failure by improving gut microbiology (synergy). Clin J Am Soc Nephrol 11:223\u2013231. https:\/\/doi.org\/10.2215\/cjn.05240515","journal-title":"Clin J Am Soc Nephrol"},{"key":"6789_CR68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.20960\/nh.1642","volume":"35","author":"R de Lopes","year":"2018","unstructured":"de Lopes R (2018) Modulation of intestinal microbiota, control of nitrogen products and inflammation by pre\/probiotics in chronic kidney disease: a systematic review. Nutr Hosp 35:722\u2013730. https:\/\/doi.org\/10.20960\/nh.1642","journal-title":"Nutr Hosp"},{"key":"6789_CR69","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.jrn.2018.08.008","volume":"29","author":"C McFarlane","year":"2019","unstructured":"McFarlane C, Ramos CI, Johnson DW, Campbell KL (2019) Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a systematic review and meta-analysis. J Ren Nutr 29:209\u2013220. https:\/\/doi.org\/10.1053\/j.jrn.2018.08.008","journal-title":"J Ren Nutr"},{"key":"6789_CR70","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3390\/nu13041273","volume":"13","author":"C Favero","year":"2021","unstructured":"Favero C, Carriazo S, Cuarental L et al (2021) Phosphate, microbiota and CKD. Nutrients 13:1273. https:\/\/doi.org\/10.3390\/nu13041273","journal-title":"Nutrients"},{"key":"6789_CR71","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3920\/bm2018.0013","volume":"9","author":"S Salvatore","year":"2018","unstructured":"Salvatore S, Pensabene L, Borrelli O et al (2018) Mind the gut: probiotics in paediatric neurogastroenterology. Benef Microbes 9:883\u2013898. https:\/\/doi.org\/10.3920\/bm2018.0013","journal-title":"Benef Microbes"},{"key":"6789_CR72","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/19490976.2020.1712982","volume":"11","author":"JL Castro-Mej\u00eda","year":"2020","unstructured":"Castro-Mej\u00eda JL, O\u2019Ferrall S, Krych \u0141 et al (2020) Restitution of gut microbiota in Ugandan children administered with probiotics (Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12) during treatment for severe acute malnutrition. Gut Microbes 11:855\u2013867. https:\/\/doi.org\/10.1080\/19490976.2020.1712982","journal-title":"Gut Microbes"},{"key":"6789_CR73","doi-asserted-by":"publisher","first-page":"CD004827","DOI":"10.1002\/14651858.cd004827","volume":"2","author":"B Johnston","year":"2004","unstructured":"Johnston B, Wiebe N, Crumley E et al (2004) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2:CD004827. https:\/\/doi.org\/10.1002\/14651858.cd004827","journal-title":"Cochrane Database Syst Rev"},{"key":"6789_CR74","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/toxins16060242","volume":"16","author":"M Vandecruys","year":"2024","unstructured":"Vandecruys M, De Smet S, De Beir J et al (2024) Revitalizing the gut microbiome in chronic kidney disease: a comprehensive exploration of the therapeutic potential of physical activity. Toxins 16:242. https:\/\/doi.org\/10.3390\/toxins16060242","journal-title":"Toxins"},{"key":"6789_CR75","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/fmb.16.12","volume":"11","author":"M Esgalhado","year":"2016","unstructured":"Esgalhado M, Borges NA, Mafra D (2016) Could physical exercise help modulate the gut microbiota in chronic kidney disease? Future Microbiol 11:699\u2013707. https:\/\/doi.org\/10.2217\/fmb.16.12","journal-title":"Future Microbiol"},{"key":"6789_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ekir.2019.11.002","volume":"5","author":"K Sumida","year":"2020","unstructured":"Sumida K, Yamagata K, Kovesdy CP (2020) Constipation in CKD Kidney Int Rep 5:121\u2013134. https:\/\/doi.org\/10.1016\/j.ekir.2019.11.002","journal-title":"Constipation in CKD Kidney Int Rep"},{"key":"6789_CR77","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3390\/microorganisms8121862","volume":"8","author":"R Ikee","year":"2020","unstructured":"Ikee R, Sasaki N, Yasuda T, Fukazawa S (2020) Chronic kidney disease, gut dysbiosis, and constipation: a burdensome triplet. Microorganisms 8:1862. https:\/\/doi.org\/10.3390\/microorganisms8121862","journal-title":"Microorganisms"},{"key":"6789_CR78","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00467-022-05849-y","volume":"38","author":"M Wan","year":"2023","unstructured":"Wan M, King L, Baugh N et al (2023) Gutted: constipation in children with chronic kidney disease and on dialysis. Pediatr Nephrol 38:3581\u20133596. https:\/\/doi.org\/10.1007\/s00467-022-05849-y","journal-title":"Pediatr Nephrol"},{"key":"6789_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fmed.2019.00019","volume":"6","author":"T Ohkusa","year":"2019","unstructured":"Ohkusa T, Koido S, Nishikawa Y, Sato N (2019) Gut microbiota and chronic constipation: a review and update. Front Med 6:19. https:\/\/doi.org\/10.3389\/fmed.2019.00019","journal-title":"Front Med"},{"key":"6789_CR80","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1053\/j.jrn.2023.06.008","volume":"33","author":"NA Borges","year":"2023","unstructured":"Borges NA, Sahiun E, Ribeiro-Alves M et al (2023) Effects of Polydextrose supplementation on intestinal function in hemodialysis patients: a double-blind, randomized, placebo-controlled trial. J Ren Nutr 33:747\u2013754. https:\/\/doi.org\/10.1053\/j.jrn.2023.06.008","journal-title":"J Ren Nutr"},{"key":"6789_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12887-024-05383-w","volume":"25","author":"S Gong","year":"2025","unstructured":"Gong S, Yu Z, Ding Y, Wang Y et al (2025) Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0\u20134 in Zunyi region. BMC Pediatr 25:45. https:\/\/doi.org\/10.1186\/s12887-024-05383-w","journal-title":"BMC Pediatr"},{"key":"6789_CR82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.clnesp.2022.08.025","volume":"51","author":"D Mafra","year":"2022","unstructured":"Mafra D, Baptista BA, Sahiun E et al (2022) May polydextrose potentially improve gut health in patients with chronic kidney disease? Clin Nutr ESPEN 51:7\u201316. https:\/\/doi.org\/10.1016\/j.clnesp.2022.08.025","journal-title":"Clin Nutr ESPEN"},{"key":"6789_CR83","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1681\/asn.2014060530","volume":"26","author":"E Mishima","year":"2015","unstructured":"Mishima E, Fukuda S, Shima H et al (2015) Alteration of the intestinal environment by Lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 26:1787\u20131794. https:\/\/doi.org\/10.1681\/asn.2014060530","journal-title":"J Am Soc Nephrol"},{"key":"6789_CR84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/ndt\/gfz126","volume":"35","author":"F Nanto-Hara","year":"2019","unstructured":"Nanto-Hara F, Kanemitsu Y, Fukuda S et al (2019) The guanylate cyclase C agonist linaclotide ameliorates the gut\u2013cardio\u2013renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dial Transplant 35:250\u2013264. https:\/\/doi.org\/10.1093\/ndt\/gfz126","journal-title":"Nephrol Dial Transplant"},{"key":"6789_CR85","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s10157-019-01727-4","volume":"23","author":"M Sueyoshi","year":"2019","unstructured":"Sueyoshi M, Fukunaga M, Mei M et al (2019) Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin Exp Nephrol 23:908\u2013919. https:\/\/doi.org\/10.1007\/s10157-019-01727-4","journal-title":"Clin Exp Nephrol"},{"key":"6789_CR86","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3390\/biomedicines10092234","volume":"10","author":"C-K Hsu","year":"2022","unstructured":"Hsu C-K, Su S-C, Chang L-C et al (2022) Oral absorbent AST-120 is associated with compositional and functional adaptations of gut microbiota and modification of serum short and medium-chain fatty acids in advanced CKD patients. Biomedicines 10:2234. https:\/\/doi.org\/10.3390\/biomedicines10092234","journal-title":"Biomedicines"},{"key":"6789_CR87","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12882-020-01971-x","volume":"21","author":"SH Kim","year":"2020","unstructured":"Kim SH, Jhee JH, Choi HY et al (2020) New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study. BMC Nephrol 21:342. https:\/\/doi.org\/10.1186\/s12882-020-01971-x","journal-title":"BMC Nephrol"},{"key":"6789_CR88","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/toxins15020115","volume":"15","author":"G Caggiano","year":"2023","unstructured":"Caggiano G, Stasi A, Franzin R et al (2023) Fecal microbiota transplantation in reducing uremic toxins accumulation in kidney disease: current understanding and future perspectives. Toxins 15:115. https:\/\/doi.org\/10.3390\/toxins15020115","journal-title":"Toxins"},{"key":"6789_CR89","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13730-020-00560-z","volume":"10","author":"G Zhou","year":"2021","unstructured":"Zhou G, Zeng J, Peng L et al (2021) Fecal microbiota transplantation for membranous nephropathy. CEN Case Rep 10:261\u2013264. https:\/\/doi.org\/10.1007\/s13730-020-00560-z","journal-title":"CEN Case Rep"},{"key":"6789_CR90","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1080\/0886022x.2021.1936038","volume":"43","author":"J Zhao","year":"2021","unstructured":"Zhao J, Bai M, Yang X et al (2021) Alleviation of refractory IGA nephropathy by intensive fecal microbiota transplantation: the first case reports. Ren Fail 43:928\u2013933. https:\/\/doi.org\/10.1080\/0886022x.2021.1936038","journal-title":"Ren Fail"},{"key":"6789_CR91","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00467-023-06168-6","volume":"39","author":"A Samaey","year":"2023","unstructured":"Samaey A, V\u00e1zquez-Castellanos JF, Caenepeel C et al (2023) Effects of fecal microbiota transplantation for recurrent clostridium difficile infection in children on kidney replacement therapy: a pilot study. Pediatr Nephrol 39:1201\u20131212. https:\/\/doi.org\/10.1007\/s00467-023-06168-6","journal-title":"Pediatr Nephrol"},{"key":"6789_CR92","doi-asserted-by":"crossref","unstructured":"Herman C, Barker BM, Bartelli TF et al (2024) Assessing engraftment following fecal microbiota transplant. ArXiv","DOI":"10.1080\/19490976.2025.2525478"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06789-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06789-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06789-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:39:26Z","timestamp":1765528766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06789-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6789"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06789-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The wrong Supplementary file was originally published with this article; it has now been replaced with the correct file.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}